CRISPR company Intellia names CFO
This article was originally published in Scrip
Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 technology for gene editing and repair, has appointed Sapna Srivastava chief financial and strategy officer. Dr Srivastava has experience in the biopharmaceutical industry and on Wall Street. Prior to joining Intellia she was senior analyst and team leader of the biotechnology group at Goldman Sachs.
You may also be interested in...
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.